During the past decade, Guizhou Cancer Hospital conducted 19 clinical trials. In the 10-year time frame, 19 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Guizhou Cancer Hospital" #1 sponsor was "Sun Yat-sen University" with 3 trials, followed by "Akeso" with 2 trials sponsored, "Jiangsu HengRui Medicine Co., Ltd." with 2 trials sponsored, "Merck Sharp & Dohme LLC" with 2 trials sponsored and "BeiGene" with 2 trials sponsored. Other sponsors include 8 different institutions and companies that sponsored additional 18 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Guizhou Cancer Hospital" #1 collaborator was "Cancer Hospital of Guizhou Province" with 2 trials as a collaborator, "Eisai Inc." with 2 trials as a collaborator, "Affiliated Hospital of Guangdong Medical University" with 1 trials as a collaborator, "Affiliated Yueqing Hospital of Wenzhou Medical University" with 1 trials as a collaborator and "Anhui Provincial Children's Hospital" with 1 trials as a collaborator. Other collaborators include 87 different institutions and companies that were collaborators in the rest 97 trials.

According to Clinical.Site data, the most researched conditions in "Guizhou Cancer Hospital" are "Nasopharyngeal Carcinoma" (3 trials), "Head and Neck Squamous Cell Carcinoma" (2 trials), "Advanced Solid Tumor" (1 trials), "Adverse Drug Reaction" (1 trials) and "Breast Diseases" (1 trials). Many other conditions were trialed in "Guizhou Cancer Hospital" in a lesser frequency.

Most popular intervention types in "Guizhou Cancer Hospital" are "Drug" (21 trials), "Radiation" (6 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Chemotherapy" (2 trials), "IMRT" (2 trials), "Lenvatinib" (2 trials) and "Pembrolizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Guizhou Cancer Hospital" are 18 trials for "All" genders, 3 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Guizhou Cancer Hospital". 1 are not yet recruiting, 9 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Guizhou Cancer Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Guizhou Cancer Hospital, 3 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".